Premium
Treatment of isolated growth hormone deficiency type IA due to GH‐I gene deletion with recombinant human insulin‐like growth factor I
Author(s) -
Nishi Y,
Hamamoto K,
Kajiyama M,
Fujiwara M,
Miyagawa S,
Hasegawa Y,
Hasegawa T
Publication year - 1993
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1993.tb12616.x
Subject(s) - medicine , recombinant dna , endocrinology , insulin like growth factor , human growth hormone , growth hormone , growth hormone deficiency , gene , human insulin , growth factor , insulin , hormone , genetics , receptor , biology
Biosynthetic insulin‐like growth factor I (IGF‐I) was administered subcutaneously twice a day for one year to a patient with isolated growth hormone deficiency (IGHD) type IA with high titres of anti‐GH antibody (up to 1:1 000 000). During IGF‐I therapy he showed good linear growth without any side effects, such as hypoglycemia and anti‐IGF‐I antibody formation. Administration of IGF‐I to IGHD type IA with poor response to GH therapy appears to have a beneficial effect on growth.